Other studies also reported that NRAS mutations were detected in ∼10–25% of melanomas [3], [5]–[7] and KRAS mutations were detected in ∼30% non-small cell lung cancers (NSCLCs) [3], [8]. Here, KRAS is linked to melanoma.